Metagenomi Therapeutics, Inc.
MGX
$1.16
-$0.01-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -59.84% | -50.66% | -51.79% | -43.88% | -39.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.84% | -50.66% | -51.79% | -43.88% | -39.62% |
| Cost of Revenue | -8.73% | -13.89% | -13.51% | -13.25% | -12.83% |
| Gross Profit | -18.54% | -15.00% | -21.69% | -17.05% | -14.22% |
| SG&A Expenses | -10.46% | -11.81% | -16.33% | -17.38% | -13.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.12% | -13.42% | -14.15% | -14.19% | -13.04% |
| Operating Income | -9.53% | -5.81% | -8.00% | -4.29% | -3.76% |
| Income Before Tax | -3.72% | -3.20% | -5.21% | -19.20% | -23.23% |
| Income Tax Expenses | 94.01% | 97.30% | 98.95% | 17.67% | -283.04% |
| Earnings from Continuing Operations | -7.28% | -10.18% | -12.57% | -19.99% | -16.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.28% | -10.18% | -12.57% | -19.99% | -16.16% |
| EBIT | -9.53% | -5.81% | -8.00% | -4.29% | -3.76% |
| EBITDA | -10.55% | -6.51% | -8.63% | -4.16% | -3.29% |
| EPS Basic | -5.98% | -8.97% | 9.97% | 68.86% | 81.88% |
| Normalized Basic EPS | -15.85% | -12.86% | 7.82% | 68.30% | 81.86% |
| EPS Diluted | -5.98% | -8.97% | 9.97% | 68.86% | 81.88% |
| Normalized Diluted EPS | -15.85% | -12.86% | 7.82% | 68.30% | 81.86% |
| Average Basic Shares Outstanding | 1.22% | 1.25% | 13.02% | 51.97% | 129.58% |
| Average Diluted Shares Outstanding | 1.22% | 1.25% | 13.02% | 51.97% | 129.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |